ProfileGDS5678 / 1456184_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 35% 34% 34% 32% 33% 35% 34% 33% 34% 33% 34% 34% 33% 34% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8300235
GSM967853U87-EV human glioblastoma xenograft - Control 22.7689134
GSM967854U87-EV human glioblastoma xenograft - Control 32.770734
GSM967855U87-EV human glioblastoma xenograft - Control 42.6802532
GSM967856U87-EV human glioblastoma xenograft - Control 52.6914933
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8700135
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8192134
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7485133
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7425534
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7413333
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7545334
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7454934
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7610933
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7571434